Understanding the Science Behind Disease Modifying Trials in Dementia with Lewy Bodies (DLB)

About this Webinar: 

Join us for Episode 5 of our Community Webinar Series, Understanding the Science Behind Disease Modifying Trials in Dementia with Lewy Bodies (DLB), on September 21 at 2:00 pm ET. 

This webinar will explore the pathology and symptoms of DLB, how these changes in the brain contribute to dementia with Lewy bodies and will aim to explain how the science targeting these changes could potentially benefit people living with DLB. 

Register for Episode 5 at https://us02web.zoom.us/webinar/register/WN_n_48Uk0JTaayF3anNRBX4g#/registration 

Dementia with Lewy bodies (DLB) has overlapping pathology and symptoms of Parkinson’s and Alzheimer’s diseases, making it challenging to diagnose. DLB is caused by a build-up of a protein, α-synuclein, which forms deposits, called Lewy bodies, in the brain. Patients with DLB often experience cognitive, physical, sleep and behavioral symptoms, including hallucinations, delusions and mood changes. 

Learning Objectives:  

Following this webinar, attendees will be able to:  

1. Define α-synuclein and amyloid-β  
2. Describe how α-synuclein and amyloid-β play a role in the brain changes associated with dementia with Lewy bodies.  
3. Summarize the potential benefits of treatments targeting α-synuclein and amyloid-β for people living with dementia with Lewy bodies. 

Unable to attend the live session? You don’t have to miss out. Register now, and we’ll send you a link to the webinar recording on YouTube after the event. Head to LBDAtv to check out our other episodes while you wait! 

Introducing Your Speaker:

James E. Galvin, M.D., M.P.H

Professor of Neurology and Psychiatry & Behavioral Sciences at the University of Miami Miller School of Medicine, Director and Principal Investigator of the Lewy Body Dementia Research Center of Excellence 

Dr. Galvin is Professor of Neurology and Psychiatry & Behavioral Sciences at the University of Miami Miller School of Medicine. He is Division Chief for Cognitive Neurology, Founding Director of the Comprehensive Center for Brain Health, and Director and Principal Investigator of the Lewy Body Dementia Association (LBDA) Research Center of Excellence at the University of Miami.  

Dr. Galvin has authored over 325 scientific publications (h-index=66) and three textbooks on healthy brain aging, cognitive health, Alzheimer’s disease, Lewy Body dementia, and related disorders. Dr. Galvin is principal investigator on nine active NIH grants and has received over $100 Million in research funding from the National Institutes of Health, Disease Associations, Private and Family Foundations.